North American Thrombosis Forum Right Heart Symposium 2023

Overview

The North American Thrombosis Forum Right Heart Symposium 2023 delivers comprehensive insights into pulmonary vascular disease (PVD) and related right heart conditions. This on-demand program includes 31 videos and 1 PDF file, totaling 11.7 GB, and addresses the evaluation, diagnosis, and management of progressive diseases such as pulmonary hypertension and right ventricular dysfunction. The course supports strengthening clinical expertise through detailed discussion of advanced imaging, pharmacologic, interventional, and hemodynamic approaches.

On-demand cardiology education — accessible anytime, anywhere.

Format: 31 videos and 1 PDF
Total size: 11.7 GB

Agenda

This program covers a broad scope of topics relevant to right heart and pulmonary vascular diseases, emphasizing practical assessment and therapeutic strategies. Sessions include detailed presentations and panel discussions focused on the latest diagnostic and treatment modalities.

• Assessing RV Function and Response to Treatment — Advanced Imaging Approaches to Assessing Pulmonary Vascular Remodeling and RV Function
• Assessing RV Function and Response to Treatment — Assessing the RV- It’s All in the Curves
• Assessing RV Function and Response to Treatment — Assessing the RV- It’s the Dots, Not the Curves- Focus on Speckle Tracking and Strain Imaging
• Assessing RV Function and Response to Treatment — Is There a Role for PET or Molecular Imaging to Assess the RV
• Assessing RV Function and Response to Treatment — Panel Discussion
• KEYNOTE PRESENTATION — Assessing Right Ventricular Function Using Exercise, Imaging, and Hemodynamics
• Novel Interventional and Pharmaceutical Approaches — In the Age of Disease Modifiers, What Should Our Approach to Treatment Be
• Novel Interventional and Pharmaceutical Approaches — Intrapulmonary Artery Balloon Pump – Why and When
• Novel Interventional and Pharmaceutical Approaches — Panel Discussion
• Novel Interventional and Pharmaceutical Approaches — Targeting BMPR2
• Novel Interventional and Pharmaceutical Approaches — Targeting Metabolism – Is It a Viable Target
• Pulmonary Embolism — Clot In Transit – What Is the Optimal Approach
• Pulmonary Embolism — Optimal Duration of Anticoagulation – 2 Months; 3 Months; Life Long
• Pulmonary Embolism — Panel Discussion
• Pulmonary Embolism — Provoked and Unprovoked – What Is the Difference, and Does It Matter
• Pulmonary Embolism — What Does Clot Burden Mean
• Pulmonary Non-Hypertensive Vascular Pathology — Anomalous Venous Return – Diagnosis and Management
• Pulmonary Non-Hypertensive Vascular Pathology — Left to Right Shunting and Enhanced Pulmonary Blood Flow – Why Is the Patient Dyspneic
• Pulmonary Non-Hypertensive Vascular Pathology — Panel Discussion
• Pulmonary Non-Hypertensive Vascular Pathology — Pulmonary Artery Aneurysm – Is It a Surgical Disease
• Pulmonary Non-Hypertensive Vascular Pathology — Pulmonary AVMs Without HHT
• The Art of Hemodynamics — What Does the RHC Really Tell Us: Clinical Implications of Aggressive Afterload Reduction
• The Art of Hemodynamics — Panel Discussion
• The Art of Hemodynamics — Pulmonary Artery Hemodynamics: The Action Is in the Proximal Vasculature
• The Art of Hemodynamics — Pulmonary Artery Hemodynamics: The Action Is in the Small Vessels
• The Art of Hemodynamics — RV-PA Coupling, Afterload, and Pressure-Volume Curves
• The Failing Right Heart — What Are the Realistic Salvage Options: Inotropic Support in RV Failure – Is There Really a Role
• The Failing Right Heart — Panel Discussion
• The Failing Right Heart — Vasopressor Support in RH Failure – Can We Optimize RV Mechanics and Coronary Perfusion
• The Failing Right Heart — When and Why Is the RV Too Sick for Lung Transplantation
• The Failing Right Heart — When to Consider MCS – Hemodynamic, Physiologic, and Patient Selection

Learning Objectives

At the end of this program, participants should be able to:

• Review the options for advanced imaging approaches to assess and monitor right ventricular function and pulmonary vascular remodeling.
• Describe pharmacologic interventions to augment or restore right ventricular function in patients with advanced pulmonary vascular disease or critical illness.
• Assess the latest interventional, device, and pharmacologic approaches to pulmonary vascular disease and evaluate these options in various forms of the disease, including pathways such as PDGF and TGF-beta signaling.
• Discuss advanced hemodynamic and physiologic correlates of right ventricular-pulmonary arterial coupling.

Speakers

This course features expert presentations and panel discussions delivered by leading clinicians and researchers in cardiology and pulmonology specializing in right heart function and pulmonary vascular disease. Detailed speaker information is provided within the course materials.

Target Audience

This program is designed for clinical and research professionals involved in the study and care of patients with right heart disease, congenital heart disease, pulmonary hypertension, and associated pulmonary vascular disorders. It is relevant for cardiologists, pulmonologists, and related healthcare providers seeking to enhance their clinical knowledge and management skills in these areas.

Why This Topic Matters

The North American Thrombosis Forum Right Heart Symposium 2023 addresses critical challenges in managing pulmonary vascular disease and right heart dysfunction, central topics in cardiology and pulmonology. Early recognition and precise assessment of these conditions are essential for optimizing patient care and clinical decision-making.

MedHub Central facilitates access to this specialized education, supporting professionals in strengthening their expertise and confidence in managing complex right heart and pulmonary vascular disorders through evidence-based approaches presented in this comprehensive program.